SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN
OBJECTIVES: To assess the safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) during the fasting month of Ramadan, in a real-life scenario, by finding the frequency and severity of severe hypoglycemia, hyperglycemia, dehydration, or diabetic ketoacidosis (DKA). RESULTS: Total of 101 par...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Khyber Medical University
2021-11-01
|
| Series: | Khyber Medical University Journal |
| Subjects: | |
| Online Access: | https://www.kmuj.kmu.edu.pk/article/view/22213 |
| _version_ | 1797807321589481472 |
|---|---|
| author | Aisha Sheikh Bhgawan Das Saadia Sattar Najmul Islam |
| author_facet | Aisha Sheikh Bhgawan Das Saadia Sattar Najmul Islam |
| author_sort | Aisha Sheikh |
| collection | DOAJ |
| description | OBJECTIVES: To assess the safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) during the fasting month of Ramadan, in a real-life scenario, by finding the frequency and severity of severe hypoglycemia, hyperglycemia, dehydration, or diabetic ketoacidosis (DKA).
RESULTS: Total of 101 participants were enrolled and because of pandemic, we were able to collect complete data on 84 (83.2%) participants. Majority (n=44; 52.4%) of participants were males. Mean age of patients was 52.4±9.5 years with an average duration of T2DM was 11.5±6.5 years. Most of the study participants (n=54; 64.3%) were on Empagliflozin (mean-dose=14.7±7.1 mg/day) and 30 (35.7%) participants were on Dapagliflozin (mean-dose=8.2±2.7 mg/day). Only six patients (7.1%) reported having mild hypoglycemia. No study participant had any severe hypoglycemia, hyperglycemia, dehydration or DKA that would have required hospital admission. Changes observed were in the HbA1c (7.6±1.2% from 7.9±2.4%, p=0.34), weight (78.1±13.1 Kgs from 78.7±13.4 Kgs, p=0.23) and in creatinine (0.9±0.2 mg/dl from 0.9±0.4 mg/dl, p<0.09) within six weeks post Ramadan.
CONCLUSION: SGLT2-I agents are safe and effective during the month of Ramadan in Pakistani patients with T2DM, without any additional adverse events. |
| first_indexed | 2024-03-13T06:20:49Z |
| format | Article |
| id | doaj.art-8ad62235c4c44083907c128f40fca8e1 |
| institution | Directory Open Access Journal |
| issn | 2305-2643 2305-2651 |
| language | English |
| last_indexed | 2024-03-13T06:20:49Z |
| publishDate | 2021-11-01 |
| publisher | Khyber Medical University |
| record_format | Article |
| series | Khyber Medical University Journal |
| spelling | doaj.art-8ad62235c4c44083907c128f40fca8e12023-06-09T19:18:39ZengKhyber Medical UniversityKhyber Medical University Journal2305-26432305-26512021-11-0113Suppl. 1S1S110.35845/kmuj.2021.222131736SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTANAisha Sheikh0Bhgawan Das1Saadia Sattar2Najmul Islam3Department of Medicine, The Aga Khan University Hospital, Karachi, PakistanCancer Foundation Hospital, Karachi, PakistanDepartment of Medicine, The Aga Khan University Hospital, Karachi, PakistanDepartment of Medicine, The Aga Khan University Hospital, Karachi, PakistanOBJECTIVES: To assess the safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) during the fasting month of Ramadan, in a real-life scenario, by finding the frequency and severity of severe hypoglycemia, hyperglycemia, dehydration, or diabetic ketoacidosis (DKA). RESULTS: Total of 101 participants were enrolled and because of pandemic, we were able to collect complete data on 84 (83.2%) participants. Majority (n=44; 52.4%) of participants were males. Mean age of patients was 52.4±9.5 years with an average duration of T2DM was 11.5±6.5 years. Most of the study participants (n=54; 64.3%) were on Empagliflozin (mean-dose=14.7±7.1 mg/day) and 30 (35.7%) participants were on Dapagliflozin (mean-dose=8.2±2.7 mg/day). Only six patients (7.1%) reported having mild hypoglycemia. No study participant had any severe hypoglycemia, hyperglycemia, dehydration or DKA that would have required hospital admission. Changes observed were in the HbA1c (7.6±1.2% from 7.9±2.4%, p=0.34), weight (78.1±13.1 Kgs from 78.7±13.4 Kgs, p=0.23) and in creatinine (0.9±0.2 mg/dl from 0.9±0.4 mg/dl, p<0.09) within six weeks post Ramadan. CONCLUSION: SGLT2-I agents are safe and effective during the month of Ramadan in Pakistani patients with T2DM, without any additional adverse events.https://www.kmuj.kmu.edu.pk/article/view/22213diabetes mellitus type 2sodium-glucose transport proteinssodium-glucose cotransporter 2 inhibitorssglt2-iramadanempagliflozindapagliflozinhypoglycemiahyperglycemiadehydrationdiabetic ketoacidosis |
| spellingShingle | Aisha Sheikh Bhgawan Das Saadia Sattar Najmul Islam SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN Khyber Medical University Journal diabetes mellitus type 2 sodium-glucose transport proteins sodium-glucose cotransporter 2 inhibitors sglt2-i ramadan empagliflozin dapagliflozin hypoglycemia hyperglycemia dehydration diabetic ketoacidosis |
| title | SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN |
| title_full | SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN |
| title_fullStr | SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN |
| title_full_unstemmed | SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN |
| title_short | SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN |
| title_sort | safety of sodium glucose cotransporter 2 inhibitors during the month of ramadan in patients with type 2 diabetes mellitus from a tertiary care centre in karachi pakistan |
| topic | diabetes mellitus type 2 sodium-glucose transport proteins sodium-glucose cotransporter 2 inhibitors sglt2-i ramadan empagliflozin dapagliflozin hypoglycemia hyperglycemia dehydration diabetic ketoacidosis |
| url | https://www.kmuj.kmu.edu.pk/article/view/22213 |
| work_keys_str_mv | AT aishasheikh safetyofsodiumglucosecotransporter2inhibitorsduringthemonthoframadaninpatientswithtype2diabetesmellitusfromatertiarycarecentreinkarachipakistan AT bhgawandas safetyofsodiumglucosecotransporter2inhibitorsduringthemonthoframadaninpatientswithtype2diabetesmellitusfromatertiarycarecentreinkarachipakistan AT saadiasattar safetyofsodiumglucosecotransporter2inhibitorsduringthemonthoframadaninpatientswithtype2diabetesmellitusfromatertiarycarecentreinkarachipakistan AT najmulislam safetyofsodiumglucosecotransporter2inhibitorsduringthemonthoframadaninpatientswithtype2diabetesmellitusfromatertiarycarecentreinkarachipakistan |